Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Leuprorelin; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

24 Jul 2024 Planned End Date changed from 1 Jun 2024 to 30 Dec 2024.
27 Jan 2024 Results from part 2, presented at the 2024 Genitourinary Cancers Symposium
01 Jan 2024 Results part 2 of a randomized phase 2 trial published in the Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com